Abstract
Biomarkers in the clinical oncology field can have tremendous therapeutic impact especially if the marker is detected before clinical symptoms. This impact can be extended to the evaluation of clinical oncology treatments allowing evaluation of potential compounds to determine their efficacy in the disease treatment. The discovery of clinical biomarkers can consume time, resources and costs. Therefore, it is important that the most effective strategies are employed to discover these biomarkers. These strategies may include the integration of available genomic, proteomic and histopathological technologies, which could reduce the costs and aid in the validation of the biomarker. Certainly the type of biomarker needed to address a particularly defined problem will drive the type of technology. However, a single biomarker to diagnose a specific cancer can be as elusive as relying on a single technology. This review examines some of the technologies used to discover biomarkers and presents the use of combinatorial technical synergies to discover and validate potential clinical oncology biomarkers.
Keywords: biomarker, oncology, integration, functional informatics, proteomics, genomics, histology
Current Topics in Medicinal Chemistry
Title: Synergistic Approaches to Clinical Oncology Biomarker Discovery
Volume: 5 Issue: 11
Author(s): Stanley M. Belkowski, Deborah Polkovitch and Michael R. D'Andrea
Affiliation:
Keywords: biomarker, oncology, integration, functional informatics, proteomics, genomics, histology
Abstract: Biomarkers in the clinical oncology field can have tremendous therapeutic impact especially if the marker is detected before clinical symptoms. This impact can be extended to the evaluation of clinical oncology treatments allowing evaluation of potential compounds to determine their efficacy in the disease treatment. The discovery of clinical biomarkers can consume time, resources and costs. Therefore, it is important that the most effective strategies are employed to discover these biomarkers. These strategies may include the integration of available genomic, proteomic and histopathological technologies, which could reduce the costs and aid in the validation of the biomarker. Certainly the type of biomarker needed to address a particularly defined problem will drive the type of technology. However, a single biomarker to diagnose a specific cancer can be as elusive as relying on a single technology. This review examines some of the technologies used to discover biomarkers and presents the use of combinatorial technical synergies to discover and validate potential clinical oncology biomarkers.
Export Options
About this article
Cite this article as:
Belkowski M. Stanley, Polkovitch Deborah and D'Andrea R. Michael, Synergistic Approaches to Clinical Oncology Biomarker Discovery, Current Topics in Medicinal Chemistry 2005; 5(11) . https://dx.doi.org/10.2174/156802605774297074
DOI https://dx.doi.org/10.2174/156802605774297074 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets FTY720: A Most Promising Immunosuppressant Modulating Immune Cell Functions
Mini-Reviews in Medicinal Chemistry Delivery of Nanoparticles for Treatment of Brain Tumor
Current Drug Metabolism Hesperetin Liposomes for Cancer Therapy
Current Drug Delivery Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry On Performance of Feature Normalization in Classification with Distance-Based Case-Based Reasoning
Recent Patents on Computer Science Design and Synthesis of 3,4-diarylpyrrole Analogues as Potent Topoisomerase Inhibitors
Medicinal Chemistry Regulation of Foxo-Dependent Transcription by Post-Translational Modifications
Current Drug Targets Recent Patents on Morphometric Analysis of Eukaryotic Cells
Recent Patents on Medical Imaging (Discontinued) Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs (Discontinued) Peptides Homing to Tumor Vasculature: Imaging and Therapeutics for Cancer
Recent Patents on Anti-Cancer Drug Discovery Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics The Clinical Characteristics and Survival Profiles of Wilms Tumor in the United Arab Emirates: A Single-center Retrospective Analysis
New Emirates Medical Journal The Global Component-Target Network in Panax Ginseng C
Letters in Drug Design & Discovery Improved Drug Delivery System for Cancer Treatment by D-Glucose Conjugation with Eugenol From Natural Product
Current Drug Delivery Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?
Current Alzheimer Research Immunohistochemical Expression of Melatonin Receptor MT1 and Glucose Transporter GLUT1 in Human Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Current Drug Targets